Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Enanta Pharmaceuticals, Inc., a biotechnology company, is engaged in the development of small molecule drugs for the infectious disease field. Its product portfolio includes ABT-450, a protease inhibitor that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV); ABT-493, a next-generation protease inhibitor for HCV infection; EDP-239, an NS5A inhibitor for HCV infection; Cyclophilin inhibitor, which are in preclinical development stage for HCV infection treatment; and Nucleotide Polymerase inhibitor program for HCV infection. The company also develops Bicyclolide antibiotic products comprising EDP-788 for the treatment of methicillin-resistant Staphylococcus aureus bacteria. It has collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc.; and AbbVie Inc. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||36.42%||Sales Growth - Q/Q||-25.98%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||47.08%||ROE||51.63%||ROI|
|Current Ratio||8.98||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.09|
|Gross Margin||Operating Margin||82.62%||Net Profit Margin||64.48%||Dividend Payout Ratio|
|Cash From Financing Activities||2.26 M||Cash From Investing Activities||-100.46 M||Cash From Operating Activities||93.25 M||Gross Profit|
|Net Profit||28.75 M||Operating Profit||48.56 M||Total Assets||245.88 M||Total Current Assets||177.78 M|
|Total Current Liabilities||19.79 M||Total Debt||180 K||Total Liabilities||21.67 M||Total Revenue||57.37 M|
|High 52 week||105.66||Low 52 week||57.95||Last close||59.48||Last change||2.09%|
|RSI||24.08||Average true range||3.15||Beta||1.05||Volume||182.38 K|
|Simple moving average 20 days||-6.19%||Simple moving average 50 days||-11.99%||Simple moving average 200 days||-28.44%|
|Performance Week||2.41%||Performance Month||-14.89%||Performance Quart||-27.21%||Performance Half||-35.06%|
|Performance Year||-20.36%||Performance Year-to-date||-16.02%||Volatility daily||3.86%||Volatility weekly||8.64%|
|Volatility monthly||17.71%||Volatility yearly||61.35%||Relative Volume||295.56%||Average Volume||208.95 K|
|New High||0.99%||New Low|
2019-11-17 08:42:54 | The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down
2019-11-11 10:21:50 | Is Enanta Pharmaceuticals, Inc.'s NASDAQ:ENTA 14% ROE Worse Than Average?
2019-11-11 07:30:00 | Enanta Pharmaceuticals Announces Poster Presentations at The Liver Meeting® 2019
2019-10-27 22:29:08 | Enanta Pharmaceuticals Inc ENTA: Hedge Funds In Wait-and-See Mode
2019-10-21 16:00:00 | Enanta Pharmaceuticals to Present at the 2019 Wolfe Research Healthcare Conference
2019-10-12 10:03:32 | Is Enanta Pharmaceuticals's NASDAQ:ENTA Share Price Gain Of 145% Well Earned?
2019-10-03 07:30:00 | New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV Demonstrates Highly Statistically Significant Reductions p<0.001 in Total Symptom Score, Mucus Weight and RSV Viral Load as Measured by RT-PCR Assay and by Plaque Assay
2019-09-26 16:16:41 | This Biotech Stock Just Careened Toward Its Lowest Point In Nearly 2 Years
2019-09-26 11:40:03 | Enanta's Stock Down Despite NASH Drug Meeting Goal in Study
2019-09-25 16:28:46 | UPDATE 1-Enanta Pharma's NASH drug meets mid-stage study goal
2019-09-25 16:12:44 | Enanta Pharma's liver disease drug meets mid-stage study goal
2019-09-12 09:48:04 | Is Enanta Pharmaceuticals NASDAQ:ENTA A Risky Investment?
2019-08-21 07:30:00 | Enanta Pharmaceuticals to Present at the Baird 2019 Global Healthcare Conference
2019-08-07 12:37:52 | Enanta Pharmaceuticals, Inc. ENTA Q2 2019 Earnings Call Transcript
2019-08-07 02:05:39 | Edited Transcript of ENTA earnings conference call or presentation 6-Aug-19 8:30pm GMT
2019-08-06 17:55:09 | Enanta Pharmaceuticals ENTA Q3 Earnings Surpass Estimates
2019-08-02 08:51:00 | Enanta’s HCV Collaboration Partner AbbVie receives Approval by the European Commission for MAVIRET™ glecaprevir/pibrentasvir to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve HCV Patients with Compensated Cirrhosis
2019-07-11 09:00:01 | Enanta Pharmaceuticals ENTA Upgraded to Strong Buy: Here's What You Should Know
2019-06-14 14:06:11 | Enanta's Respiratory Virus Drug Aces Midstage Study
2019-06-14 11:12:07 | How Much Did Enanta Pharmaceuticals, Inc.'s NASDAQ:ENTA CEO Pocket Last Year?
2019-06-14 09:51:28 | UPDATE 1-Enanta's lung infection therapy succeeds in mid-stage trial
2019-06-14 06:00:00 | Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved its Primary and Secondary Endpoints in its Phase 2a Human Challenge Study in Healthy Adults Infected with Respiratory Syncytial Virus RSV
2019-06-10 16:00:00 | Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
2019-06-10 08:00:00 | AbbVie's MAVIRET™ now listed on the Nova Scotia and Manitoba formularies
2019-05-30 08:00:00 | AbbVie's MAVIRET™ now listed in New Brunswick
2019-05-15 11:11:03 | Do Enanta Pharmaceuticals's NASDAQ:ENTA Earnings Warrant Your Attention?
2019-05-14 16:01:00 | Enanta Pharmaceuticals to Present at Upcoming Investor Conference
2019-05-08 00:02:11 | Edited Transcript of ENTA earnings conference call or presentation 7-May-19 8:30pm GMT
2019-05-07 21:00:10 | Enanta Pharmaceuticals, Inc. ENTA Q2 2019 Earnings Call Transcript
2019-05-07 17:25:09 | Enanta Pharmaceuticals ENTA Beats Q2 Earnings Estimates
2019-05-07 16:16:26 | Enanta Pharmaceuticals: Fiscal 2Q Earnings Snapshot
2019-05-02 14:22:17 | Here’s What Hedge Funds Think About Enanta Pharmaceuticals Inc ENTA
2019-04-15 09:40:02 | VKTX or ENTA: What to Expect from Revenue Growth in 2019
2019-04-15 08:05:54 | What Are Analysts Recommending for VKTX and ENTA?
2019-04-11 09:00:00 | AbbVie's MAVIRET™ now reimbursed in Quebec